ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2009
WALTHAM, Mass., Feb 02, 2009 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the BIO CEO & Investor Conference 2009 will be webcast live. The presentation is scheduled to begin at 9:30 a.m. ET on February 9, 2009, and will be given at the Waldorf=Astoria hotel in New York City. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until February 16, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and the naked antibody AVE1642 is in clinical trials through the Company's collaboration with sanofi-aventis. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
